Nrx Pharmaceuticals Inc Stock Price, News & Analysis

HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals (NASDAQ:NRXP), announces an upcoming investor workshop for Qualified Institutional Investors at Mar-A-Lago Club during the week of January 6, 2025. The event aims to support planned acquisitions for a national network of interventional psychiatry practices focused on treating suicidal depression and PTSD.

The company has secured non-binding Letters of Intent and banking intent for initial clinic acquisitions, targeting facilities that generate over $100 million revenue run-rate in 2025. Future acquisitions will focus on clinics with established patient populations offering multimodal care, including ketamine treatment and Transcranial Magnetic Stimulation (TMS).

The workshop requires a minimum commitment of $5 million in secured acquisition funding from qualified investors. The presentation will comply with JOBS act 'testing the waters' provisions, and federal security clearance will be required for attendance.

NRx Pharmaceuticals (NASDAQ:NRXP) announced its subsidiary HOPE Therapeutics plans to acquire Kadima Neuropsychiatry Institute in La Jolla, CA. The institute will serve as the flagship clinic for HOPE's planned international network of interventional psychiatry clinics treating depression, anxiety, and PTSD.

Kadima is a premier interventional psychiatry clinic offering treatments including Ketamine Therapy, Spravato®, and Transcranial Magnetic Stimulation. The institute has contracts with the US Department of Veterans Affairs and treats active-duty military personnel. The acquisition is expected to be immediately accretive to NRXP's revenue and EBITDA.

Dr. David Feifel, Kadima's founder and CEO, will join HOPE as Chief Medical Innovation Officer. Dr. Feifel, a Professor Emeritus of Psychiatry at UC San Diego with 150 peer-reviewed publications, will focus on evaluating new CNS disorder treatments and leading global clinical trials.

NRx Pharmaceuticals (NASDAQ:NRXP) has submitted the first section of its New Drug Application (NDA) for NRX-100 (ketamine) to the FDA for treating suicidal depression. The company aims to be the first to receive FDA approval for this indication, addressing a market of over 13 million Americans who consider suicide annually.

The initial submission includes an 1800-page manufacturing section (Module 3), with final efficacy data and remaining sections expected in Q1 2025. NRX-100's formulation differs from anesthetic ketamine by excluding toxic preservatives and featuring diversion-resistant packaging. The drug, which received Fast Track Designation in 2017, represents a potential $3-5 billion market based on CDC data indicating 3.8 million Americans plan suicide annually.

NRx Pharmaceuticals (NRXP) announced its participation in the NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference. Dr. Jonathan Javitt, Chairman, CEO and Chief Scientist, will present on December 3, 2024, at 1:00 PM EST at Florida Atlantic University. A high-definition video webcast will be available the following day on the company's website, Noble Capital Markets' Conference website, and Channelchek platform, where it will remain archived for 90 days.

NRx Pharmaceuticals announced the publication of a paper in the American Journal of Clinical Psychopharmacology highlighting their improved methodology for depression rating quality assurance in clinical trials. The company developed an enhanced training and monitoring program for study site raters that achieved 94.5% concordance with central raters, allowing for a maximum variance of 3 points on a 60-point scale. This improved accuracy enabled their phase 2b/3 clinical trial of NRX-101 to achieve statistical significance with fewer than 100 participants, compared to the several hundred typically required. The methodology demonstrated significant improvements in measuring recovery from suicidality and reduction in akathisia.

NRx Pharmaceuticals (NRXP) has appointed Michael Abrams as permanent Chief Financial Officer, replacing Interim-CFO Richard Narido. Abrams brings nearly three decades of experience as an executive officer, investment banker, and senior advisor, including CFO roles at Arch Therapeutics, RiseIT Solutions, and FitLife Brands. He specializes in financial operations, accounting, M&A, and capital raising. Narido will continue supporting the company's financial function and focus on HOPE Therapeutics projects. The appointment aligns with NRx's goal of transitioning from a pre-revenue biotechnology company to a profitable enterprise.

NRx Pharmaceuticals (NRXP) reported significant progress in Q3 2024, with plans to file NDAs for NRX-100 (IV Ketamine) and NRX-101 for treating suicidal ideation in depression by year-end 2024. The company achieved a 74% reduction in net operating losses compared to Q3 2023, reducing from $6.1M to $1.6M. HOPE Therapeutics, their subsidiary, is acquiring Interventional Psychiatry Clinics and expects first revenue by year-end 2024. The company secured $10.8M in convertible-debt funding and forecasts profitability in 2025 from HOPE Therapeutics and medication sales.

NRx Pharmaceuticals (NASDAQ: NRXP) has rescheduled its third quarter and year to date 2024 financial results conference call to Monday, November 18, 2024, at 4:30 PM ET. The change was made to accommodate potential additional corporate news. Investors can access the conference call through a live webcast on the company's website or via telephone using domestic (+1-800-717-1738) or international (+1-646-307-1865) dial-in numbers.

NRx Pharmaceuticals (NASDAQ: NRXP) announced it will release its third quarter and year to date 2024 financial results after market close on Thursday, November 14, 2024. The company will host a conference call at 4:30 PM ET on the same day to discuss the results and provide a corporate update. The conference call will be accessible via webcast on the company's website and through telephone dial-in options for both domestic (+1-800-717-1738) and international (+1-646-307-1865) participants.